Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Status:
Recruiting
Trial end date:
2024-07-05
Target enrollment:
Participant gender:
Summary
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human
Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection.
The study will compare oral ISL taken once a month with standard-of-care medication for
prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per
day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the
incidence rate per year of confirmed HIV-1 infections.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Islatravir Tenofovir